Pharm 101: Irbesartan

Class

Angiotensin-II Receptor Bloker

Pharmacodynamics
  • Competitive selective antagonist of angiotensin II type 1 (AT1) receptor
  • Causes vasodilation and inhibition of aldosterone secretion
  • More selective blockers of angiotensin effects than ACE-I, benefits include:
    • More complete inhibition of angiotensin action, because there are enzymes other than ACE capable of generating angiotensin II
    • No effect on bradykinin metabolism so reduced incidence of cough, angioedema
Pharmacokinetics
  • 90% protein bound
  • Half-life 12 hours
  • Liver metabolism
Clinical uses
  • Hypertension
  • CCF
  • Chronic renal failure:
    • Diminish proteinuria and stabilise renal function (even in absence of lowering BP)
Adverse effects
  • Similiar to those of ACE-inhibitors, except for cough and angioedema which are uncommon
Precautions/contraindications
  • Non-diabetic renal failure
  • Pregnancy
  • Hyperkalaemia
  • Renal artery stenosis
Further Reading
Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS (UWA) CCPU (RCE, Biliary, DVT, E-FAST, AAA) Emergency Medicine Advanced Trainee in Melbourne, Australia. Special interests in diagnostic and procedural ultrasound, medical education, and ECG interpretation. Editor-in-chief of the LITFL ECG Library. Twitter: @rob_buttner

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.